Demo Sign up Log In

Lineage Cell Therapeutics, Inc. Common Stock (LCTX)

R&D Expenses

$20.52M

TTM · Period ending: Jun 30, 2026 · USD

LCTX R&D Expenses

Latest reported$20.52Mperiod endingJun 30, 2026

Latest reported$20.52Mperiod endingJun 30, 2026

LCTX TTM R&D Expenses ($0.00 → $20.52M)

TTM R&D Expenses

High-resolution chart · PNG

LCTX r&d expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Lineage Cell Therapeutics, Inc. Common Stock R&D Expenses — Trailing twelve months (TTM) (USD)
Period ending	R&D Expenses (USD)
Jun 30, 2001	2,618,550
Mar 31, 2001	3,006,803
Dec 31, 2000	3,362,841
Sep 30, 2000	3,787,633
Jun 30, 2000	4,940,598
Mar 31, 2000	5,110,451
Dec 31, 1999	4,900,521
Sep 30, 1999	4,700,000
Jun 30, 1999	3,300,000
Mar 31, 1999	3,100,000
Sep 30, 1998	3,300,000
Jun 30, 1998	3,100,000
Mar 31, 1998	3,300,000
Dec 31, 1997	2,800,000
Sep 30, 1997	2,400,000
Jun 30, 1997	2,100,000
Mar 31, 1997	1,300,000
Dec 31, 1996	900,000
Sep 30, 1996	400,000
Jun 30, 1996	200,000
Mar 31, 1996	800,000
Dec 31, 1995	1,200,000
Sep 30, 1995	1,700,000
Jun 30, 1995	1,800,000
Mar 31, 1995	1,500,000
Dec 31, 1994	1,200,000
Sep 30, 1994	700,000
Jun 30, 1994	400,000
Mar 31, 1994	100,000
Dec 31, 1993	0
Sep 30, 1993	0
Jun 30, 1993	0
Mar 31, 1993	0
Dec 31, 1992	0

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.